Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1995
Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
van Besien K W, Khouri I F, Giralt S A, McCarthy P, Mehra R, Andersson B S, Przepiorka D, Gajewski J L, Bellare N, Nath R
Аннотация
PURPOSE: To evaluate the role of allogeneic bone marrow transplantation (BMT) in recurrent low-grade lymphoma.
PATIENTS AND METHODS: Between 1989 and 1994, 10 patients with chemotherapy-refractory and recurrent low-grade lymphoma were treated with myeloablative therapy and allogeneic BMT. All patients had poor prognostic features and had been extensively pretreated.
RESULTS: Eight patients achieved a complete remission and none have relapsed at a median follow-up time of 816 days (range, 346 to 1,865). Two patients died of early complications. The actuarial survival and failure-free survival rates are both 80% +/- 12.6%. For surviving patients, the duration of the current remission exceeds that of any previous remission achieved.
CONCLUSION: These results compare favorably with those for autologous BMT. Allogeneic BMT offers considerable promise for the treatment of patients with poor-prognosis low-grade lymphoma. Its role should be further defined in prospective studies.
PATIENTS AND METHODS: Between 1989 and 1994, 10 patients with chemotherapy-refractory and recurrent low-grade lymphoma were treated with myeloablative therapy and allogeneic BMT. All patients had poor prognostic features and had been extensively pretreated.
RESULTS: Eight patients achieved a complete remission and none have relapsed at a median follow-up time of 816 days (range, 346 to 1,865). Two patients died of early complications. The actuarial survival and failure-free survival rates are both 80% +/- 12.6%. For surviving patients, the duration of the current remission exceeds that of any previous remission achieved.
CONCLUSION: These results compare favorably with those for autologous BMT. Allogeneic BMT offers considerable promise for the treatment of patients with poor-prognosis low-grade lymphoma. Its role should be further defined in prospective studies.
Предметные рубрики MeSH
AdultAntineoplastic Combined Chemotherapy ProtocolsBone Marrow TransplantationBusulfanCisplatinCombined Modality TherapyCyclophosphamideEtoposideFemaleFollow-Up StudiesHematopoietic Stem Cell TransplantationHumansKarnofsky Performance StatusLymphoma, Non-HodgkinMaleMethotrexateMiddle AgedPlatelet TransfusionRecurrenceRemission InductionSurvival AnalysisThiotepaTransplantation, HomologousWhole-Body Irradiation